Antibody–drug conjugates to treat gastric cancer
Shigehiro Koganemaru, Kohei Shitara
Abstract
INTRODUCTION: Despite new treatment options, the long-term prognosis of recurrent or inoperable gastric cancer remains poor. Antibody-drug conjugates (ADCs) are a new class of drugs and have shown promising results in clinical trials. AREAS COVERED: This review focuses on recent clinical findings and development of ADCs for gastric cancer, and summarizes the relevant resistance mechanisms or future directions of ADCs. EXPERT OPINION: gastric cancer; however, several questions remain, especially in clinical settings. Translational research to elucidate ADCs' mechanisms of action or resistance will lead to more sophisticated use of ADCs and combination strategies.
Topics & Concepts
MedicineCancerClinical trialDrugExpert opinionPharmacologyIntensive care medicineInternal medicineHER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesMonoclonal and Polyclonal Antibodies Research